Previous 10 | Next 10 |
home / stock / tbgnf / tbgnf news
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150 ,000 capital increase. This is part of Atlas Special Opportunities, LLC ’s EUR 20 million Capit...
Top-line Data Expected in Q4 2023 Leuven, BELGIUM, Boston, MA, US – June 12 , 2023 – 8 : 00 a m CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standa...
Regulated Information Leuven, Belgium, Boston, MA, US – June 5 , 202 3 – 0 7 .00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with cli...
Leuven, BELGIUM, Boston, MA, US – June 1 , 202 3 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage asse...
Regulated Information Top-line Data Anticipate d in Q4 2023 Leuven, BELGIUM, Boston, MA, US – May 2 5 , 2023 – 9 : 00 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical compan...
Leuven, BELGIUM, Boston, MA, US – May 22 , 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorde...
Regulated Information Leuven, Belgium, Boston, MA, US – May 15 , 202 3 – 0 8 .00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with...
Leuven, BELGIUM, Boston, MA, US – April 27 , 2023 – 7:00 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retina...
Regulated Information Leuven, BE LGIUM , Boston, MA, US – March 31 , 2023 – 07 .00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapie...
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300 ,000 capital increase. This is part of Atlas Special Opportunities, LLC ’s EUR 20 million Capital Comm...
News, Short Squeeze, Breakout and More Instantly...
` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET , Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress ...
Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The...
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program Eleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates ...